Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
In line with this, we did not see any significant expression of GLP-1R in our transcriptomic data
More specifically, among these cases, 19 (48.7%) were associated with liraglutide, 9 (23.1%) with dulaglutide, 4 (10.3%) each with exenatide and semaglutide, while 1 (2.6%) case each was linked to lixisenatide, albiglutide, and tirzepatide
Plant compounds such as berberine take a different route
It only takes a few minutes and helps our clinical team understand your goals and the safest, most effective path forward for your treatment
eligible Medicare patients can access FDA-approved GLP-1 medications for $50/month through the CMS Medicare GLP-1 Bridge Program - a different pathway worth evaluating before enrolling in a cash-pay compounded program FDA adverse event data (as of May 21, 2026): FDA had received more than 1,700 adverse events associated with compounded semaglutide and tirzepatide combined - a safety signal not specific to Omzo but material context for any compounded GLP-1 enrollment decision
